The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer

Published on Wednesday, 14 October 2015


Twelve patients with rectal carcinoma were treated for 2 weeks with the somatostatin analogue SMS 201.995.

Effects of this therapy were assessed using serum marker concentration, Ki67 and gastrin-immunoreactivity of the primary tumour.

In four out of 12 patients, a significant decrease in Ki67 immunoreactivity was seen during SMS 201.995 treatment while in the remaining eight patients there was no significant change in Ki67 expression.

Four patients had elevated pretreatment serum carcinoembryonic antigen (CEA) levels. In two of these four patients, serum CEA levels fell modestly during SMS 201.995 therapy.

This is the first clinical evidence that a somatostatin analogue can inhibit the growth of some colorectal cancers.



About this publication.


See also Somatostatin in oncology, the overlooked evidences.